Amylin‑Based Therapeutics Summit | December 1-3, 2026 | Boston, MA

The amylin analog space is rapidly expanding in 2026, with new companies entering the field, stealth programs beginning to emerge, and major investment from Roche–Zealand Pharma and AbbVie–Gubra reinforcing growing confidence in the modality. With biology still being unlocked and multiple development paths on the table, there remains headroom to define best‑in‑class amylin therapeutics, open new indications, and shape how this therapeutic area will deliver differentiated, durable benefit. For companies that get the science right, the competitive upside is significant.

The inaugural Amylin‑Based Therapeutics Summit 2026 arrives at this critical inflection point. This is the first and only industry‑dedicated forum bringing biopharma and academia together to dive deep and explore the full breadth of amylin drug development – from foundational receptor biology to late‑stage clinical strategy. Across two immersive days, learn from and connect with pioneering minds from Novo Nordisk, Eli Lilly, Zealand Pharma, iBio, I2O Therapeutics and emerging innovators who are collectively shaping the field.

View the full event guide: https://ter.li/2ao09t84